protea/protease

Based on the published gene sequence of tetraploid potato (Solanum.tuberosum) protease-inhibitor II, a genomic DNA and a cDNA sequence of potato protease-inhibitor II gene were obtained from the cDNA library and the genomic DNA of a diploid potato IVP101 (Solanum.phurejia) using PCR method and named

PROTEA is a randomized controlled trial to assess the efficacy and safety of darunavir/ritonavir (DRV/r) monotherapy as an alternative to triple therapy. Patients fully suppressed on first-line antiretrovirals (viral load < 50 HIV-1 RNA copies/mL) were switched to DRV/r 800/100 mg once daily, either

1. Whereas the injections of trypsin in the peritoneum of the rat cause every time a polyseritis (ascites and pleuritis) the trypsin inactivated by di-iso-propyl-fluoro-phosphate remains without effect; this fact proves therefore that the proteasic properties of the trypsin are responsible of this

BACKGROUND During treatment with protease inhibitor monotherapy, the number of antiretrovirals with therapeutic concentrations in the cerebrospinal fluid (CSF) is lower, compared to standard triple therapy. However, the clinical consequences are unclear. METHODS A total of 273 patients with HIV RNA

BACKGROUND In previous studies, protease inhibitor (PI) monotherapy has shown trends for higher low-level elevations in HIV-1 RNA compared to triple therapy, but no increase in the risk of drug resistance. METHODS A total of 273 patients with HIV-1 RNA <50 copies/mL for over 24 weeks on current